Focusing on TNF-α inhibitors, a 52-week, randomized, double-blind phase IIIb study of 194 RA patients with an inadequate response to csDMARDs demonstrated that higher levels of pre-treatment inflammatory markers (CRP) were associated with a better treatment response for a TNF-α inhibitor [4]. This evidence concerns the gene CRP and rheumatoid arthritis.